Clinical Trial & Safety Info

Learn more about the molecular properties and extensive experience of darunavir.

References: 1. Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. [published online ahead of print December 27, 2019]. doi:10.1093/cid/ciz1213. 2. Orkin C, Eron JJ, Rockstroh J, et al; AMBER Study Group. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir/alafenamide in treatment-naïve HIV-1 patients [published online December 10, 2019]. AIDS. doi:10.1097/QAD.0000000000002463. 3. Orkin C, Molina JM, Negredo E, et al; EMERALD Study Group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomized, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34.